From: Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer’s disease
MCI subgroup | p value | |||||
---|---|---|---|---|---|---|
MCINon+ | MCIAβ+ | MCIAβ+T+ | MCIAll+ | MCIT+ | ||
N | 111 | 45 | 119 | 145 | 49 | |
Age (years) | 71.29 (7.83) | 74.78 (6.59) | 74.25 (7.06) | 72.68 (7.40) | 71.57 (9.00) | 0.010 |
Education (years) | 16.54 (2.70) | 16.29 (3.07) | 16.13 (2.77) | 15.97 (2.83) | 15.92 (2.86) | 0.468 |
MMSE | 28.13 (1.70) | 27.64 (1.79) | 27.42 (1.88) | 26.93 (1.87) | 27.92 (1.78) | <0.001 |
Sex (male:female) | 67:44 | 34:11 | 78:41 | 73:72 | 29:20 | 0.020 |
APOE ε4 carriers (%) | 21.62 | 42.22 | 62.18 | 77.93 | 26.53 | <.001 |
CSF Aβ42 (pg/ml) | 232.59 (30.25) | 140.81 (26.14) | 132.81 (23.70) | 134.98 (20.96) | 232.93 (30.24) | <0.001 |
CSF Aβ42 negative/borderline/positive for AD | 87/24/0 | 0/0/45 | 0/0/119 | 0/0/145 | 39/10/0 | <0.001 |
CSF p-Tau (pg/ml) | 18.63 (4.44) | 20.36 (4.45) | 43.66 (16.00) | 58.41 (2.53) | 41.77 (13.58) | <0.001 |
CSF p-Tau negative/borderline/positive for AD | 57/54/0 | 18/27/0 | 0/2/117 | 0/0/145 | 0/0/49 | <0.001 |
CSF t-Tau (pg/ml) | 50.66 (18.12) | 55.53 (17.28) | 78.37 (18.06) | 158.09 (46.47) | 74.86 (34.40) | <0.001 |
CSF t-Tau negative/borderline/positive for AD | 106/5/0 | 42/3/0 | 59/58/2 | 0/0/145 | 29/15/5 | <0.001 |
Follow-up period (months) | 32.22 (23.34) | 32.53 (23.50) | 30.81 (22.34) | 29.96 (21.01) | 32.02 (11.64) | 0.350 |
Dementia due to AD vs no dementia at follow-up | 14:97 | 14:31 | 43:76 | 80:65 | 8:41 | <0.001 |